Dallas, Texas 02/07/2014 (FINANCIALSTRENDS) – ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) updates for 2014, indicates the body of work for this immune therapy-based product development biotechnology company is on vaccines for Cancer.
The differentiator for this year is the innovative technology deployed for this therapy.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) proposes new cancer vaccines which are expected to create better value for the investing company. This year will see the ICT 107 phase II program, ICT-121 as well as the ICT-140 programs running their course, bringing in immediate profit.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) is a Calabasas, LA based biotechnology company which offers a range of clinical-stage products. As indicative of its name the company offers a range of immunity-based therapies which treat cancer of the brain as well as ovaries. The products that Immunocellular offers are known to treat solid tumors as well.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) develops its products based on the principle of Immunotherapy. This means that the patient itself is made to produce the required molecular signal systems which can effectively bring down the cancer causing antigens in a tumor. Molecular signals are nature’s method of dealing with foreign bodies within the human system.
Current ranges of candidates which ImmunoCellular offers are – ICT-107, ICT-140 as well as the DIAAD. In the Phase II, the dendritic cell vaccine which is offered for treatment is the gliolastmoma multiforme or GBM, which is known to be one of the most fatal forms of brain cancer. Meanwhile the ICT-107 is well known to target over six different antigents which cause the cancer. The ICT-140 has to be mentioned as it is a dendritic cell vaccine which is used in the treatment of cancer of the ovaries as well as different stem cell manifestations as well.
ImmunoCellular chief executive Ndrew Gengos is expected to provide corporate overview in a conference on Feb 10, 2014. He would present ImmunoCellular activities at the 16th Annual BIO CEO and Investor Conference.